An international group have discovered associations between pathogenic variants of the BRCA 1 and 2 genes and four types of cancer. Published in ESMO Open, the findings expand the potential for personalized medicine to several cancer types that currently have limited treatment options and poor prognoses.

Esophageal squamous cell carcinoma (ESCC) is the predominant histological subtype of esophageal cancer, accounting for approximately 90% of cases worldwide, with a particularly high incidence in Asian populations. ESCC is characterized by aggressive behavior and pronounced tumor heterogeneity. Although surgical resection remains the primary curative treatment, patients with locally advanced disease frequently experience recurrence and distant metastasis, resulting in poor clinical outcomes.

A University of Calgary study led by members of the Arnie Charbonneau Cancer Institute, published in Nature Medicine, takes a closer look at why patients often relapse after immunotherapy by studying how the myeloma cells adapt to treatment.  By understanding how the cancer builds resistance, future treatments can be designed to take this into account with the goal of preventing another relapse.

A research paper by scientists at Gongli Hospital of Pudong New Area presented developed a sonodynamic nanoplatform that simultaneously eradicates primary breast tumors via ferroptosis and apoptosis and blocks their spread to bone tissues.

The research paper, published on Mar 23, 2026 in the journal Cyborg and Bionic Systems.

Colorectal cancer often returns not because the main tumor survives, but because a small population of stem-like cancer cells can resist treatment, seed new growth, and drive aggressive spread.

Acute myeloid leukemia (AML) has a poor prognosis, especially in elderly and relapsed/refractory patients, with 5‑year survival below 30%. Chemotherapy alone suffers from off‑target toxicity and drug resistance. Immunotherapy offers precision and durable effects but shows limited efficacy as monotherapy. Combining chemotherapy with immunotherapy is emerging as a promising paradigm. This review summarizes the rationale and advances of combining immune checkpoint inhibitors, CAR‑T, CAR‑NK, CAR‑macrophage therapies, antibody‑drug conjugates, bispecific antibodies, and cancer vaccines with chemotherapy for AML. We discuss preclinical and clinical progress, core challenges (off‑target toxicity, tumor heterogeneity, variable efficacy), and future directions toward precision medicine.